Compare Crispr Therapeutics AG (CRSP) vs Symbotic Inc (SYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Symbotic Inc — how do they compare? Crispr Therapeutics AG trades at $54.31 (market cap $5.17B), while Symbotic Inc trades at $41.84 (market cap $5.21B). The key difference: Crispr Therapeutics AG and Symbotic Inc are close in size by market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, Symbotic Inc nearer its low. Which is the better fit depends on your goals.
| CRSP | SYM | |
|---|---|---|
Market Cap | $5.17B | $5.21B |
Sector | Health | Technology |
52-Week High | $76.78 | $87.30 |
52-Week Low | $44.34 | $38.57 |
Enterprise Value | $3.59B | $3.46B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.52, up 3.64% in the last session, with a bullish technical outlook from moving averages but overbought RSI signals. The company reported a Q2 2026 loss of $0.94 per share, beating estimates, while revenue growth is driven by Casgevy sales. Analyst consensus is a Buy with a $76 price target, reflecting optimism for pipeline catalysts.
The outlook is supported by strong product sales and clinical progress, but significant risks include persistent negative margins, high cash burn, and reliance on pipeline success. Investors face a high-risk, high-reward scenario with the stock trading near resistance levels amid volatile earnings history.
SYM trades at $40.18, down 1.46% with bearish technical signals despite analyst optimism. Recent Q3 2026 earnings missed estimates at $0.09 vs. $0.13 expected, though revenue grew 21.7% year-over-year. The company shows weak profitability with a 0.31% net margin but maintains strong cash flow generation of $517 million in 2025. Technical indicators show bearish momentum with support at $39 and resistance at $42.
Outlook remains mixed with 61% analyst buy ratings and $60 consensus target suggesting 49% upside, but execution risks persist after recent earnings misses. Key catalysts include margin expansion and system deployments, while risks include competitive pressure and volatile earnings performance. The stock offers growth potential but requires careful monitoring of quarterly execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Symbotic Inc
Symbotic is an automation technology leader that provides an end-to-end, A.I.-powered robotic platform for large-scale warehouse operations. By utilizing untethered, high-speed autonomous bots and sophisticated vision systems, Symbotic transforms traditional distribution centers into high-density strategic assets. The company serves the world’s largest retailers and wholesalers—most notably Walmart—while expanding into 'Warehouse-as-a-Service' through its GreenBox joint venture to democratize advanced automation for smaller enterprises.
Read more on SYM →
